STAT+: Pharmalittle: We’re reading about the FDA pushing OTC meds, its new trial standards, and much more

FDA Commissioner Marty Makary expressed the belief that "everything should be over the counter" unless a drug is deemed unsafe, addictive, or requires monitoring. This statement reflects a potential shift in the FDA's approach to the regulation of medications, suggesting a broader availability of over-the-counter (OTC) drugs. In her first speech to FDA staff, the top drug regulator at the FDA, Høeg, announced plans to scrutinize the safety of selective serotonin reuptake inhibitors (SSRIs) during pregnancy. SSRIs are widely used to treat depression and anxiety disorders in expectant mothers, and there are ongoing concerns regarding their implications for fetal development and maternal health. Høeg's focus on this issue indicates a commitment to evaluating the risks associated with commonly prescribed medications for vulnerable populations, particularly pregnant individuals. Additionally, Høeg emphasized the importance of examining the administration of respiratory syncytial virus (RSV) shots to infants. The RSV vaccine is crucial for preventing severe illness in young children, and Høeg's commitment to scrutinizing its safety underscores the FDA's role in overseeing vaccines that protect against serious respiratory infections. This proactive approach to drug safety and efficacy highlights the FDA's dedication to prioritizing patient health in its regulatory processes. Overall, Høeg's address signals a potential shift in the FDA's evaluation methods, focusing on the safety of medications and vaccines for vulnerable populations, including pregnant individuals and infants. The scrutiny of SSRIs and RSV shots reflects a broader commitment to ensuring that health and safety are prioritized in the regulatory framework.